Katrin Håkansson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katrin Håkansson has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Jeppe Friborg
Department of Oncology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
11 shared publications - Ivan Richter Vogelius
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
6 shared publications - Anne Marie Lindegaard
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
5 shared publications - Lena Specht
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
5 shared publications - Søren Møller Bentzen
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland; Epidemiology and Public Health, University of Maryland, Baltimore, Maryland
4 shared publications - Claus Andrup Kristensen
Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111830
Planned versus accumulated dose in radiotherapy of oropharyngeal carcinoma – Do recurrences occur in unintended cold spots?
- 21 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111830
Open AccessPlanned versus accumulated dose in radiotherapy of oropharyngeal carcinoma – Do recurrences occur in unintended cold spots?
- Open Access
- 16 September 2026
- Published by Wiley in Head & Neck
Pattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low‐Incidence Population: A DAHANCA Study
Background: Nasopharyngeal carcinoma (NPC) is uncommon in many populations. Most existing clinical evidence comes from endemic areas, where Epstein–Barr virus (EBV)‐associated subtypes predominate. We analyzed patterns of failure in a population‐based cohort from Denmark, a low‐incidence setting. Methods: Patients with NPC treated with curative intent between 2000 and 2018 were identified through the Danish Head and Neck Cancer Study Group (DAHANCA) database and subsequently validated. Results: We identified 331 patients. The 5‐year cumulative incidence of failure was 31.1% for any failure, 16.9% for locoregional failure, and 14.2% for distant failure. Distant failure occurred almost exclusively in locally advanced disease (Stage I: 0%; II: 4.2%; III: 21.1%; and IVa: 19.4%). Rates of any failure were comparable between EBV‐positive (29.7%) and EBV‐negative (32.0%) tumors. Conclusions: In this low‐incidence population, the likelihood of failure after primary radiotherapy for NPC did not differ by EBV status. Distant failure was largely confined to patients with locally advanced stages.
- 16 September 2026
- Published by Wiley in Head & Neck
Open AccessPattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low‐Incidence Population: A DAHANCA Study
Background: Nasopharyngeal carcinoma (NPC) is uncommon in many populations. Most existing clinical evidence comes from endemic areas, where Epstein–Barr virus (EBV)‐associated subtypes predominate. We analyzed patterns of failure in a population‐based cohort from Denmark, a low‐incidence setting. Methods: Patients with NPC treated with curative intent between 2000 and 2018 were identified through the Danish Head and Neck Cancer Study Group (DAHANCA) database and subsequently validated. Results: We identified 331 patients. The 5‐year cumulative incidence of failure was 31.1% for any failure, 16.9% for locoregional failure, and 14.2% for distant failure. Distant failure occurred almost exclusively in locally advanced disease (Stage I: 0%; II: 4.2%; III: 21.1%; and IVa: 19.4%). Rates of any failure were comparable between EBV‐positive (29.7%) and EBV‐negative (32.0%) tumors. Conclusions: In this low‐incidence population, the likelihood of failure after primary radiotherapy for NPC did not differ by EBV status. Distant failure was largely confined to patients with locally advanced stages.
- Open Access
- 31 January 2025
- Published by Wiley in Head & Neck
- Vol. 47 (7) , 1831-1838
Risk Stratification for Trial Enrichment Considering Loco‐Regional Failure in Head and Neck Cancer: UICC8 Versus Purpose‐Built Failure‐Type Specific Risk Prediction Model
Background: A previously published failure‐type specific risk model showed good performance in the original cohort. Aim: to validate the model and separate patients with high‐ and low‐risk loco‐regional failure (LRF). Goal: to identify patients potentially suitable for treatment intensification trials.Methods: Validation data: 756 patients from two institutions (different countries). Predictive performance was evaluated by Brier scores and AUCs. Discriminatory performance was compared to Union for International Cancer Control (UICC) staging (versions 7 and 8).Results: The model's 3‐year AUC for LRF was 65%, significantly better than UICC7 staging, but no significant difference to UICC8. Model‐based risk stratification and UICC8 both identified high‐risk patient groups with 3‐year LRF ≈30%. The population mean was 18%.Conclusions: The model performed well on a group level. UICC8 staging performed equally well. Although developed for the endpoint of OS, an improvement from UICC version 7 to version 8 was evident also for the prediction of LRF.
- 31 January 2025
- Published by Wiley in Head & Neck
- Vol. 47 (7) , 1831-1838
Open AccessRisk Stratification for Trial Enrichment Considering Loco‐Regional Failure in Head and Neck Cancer: UICC8 Versus Purpose‐Built Failure‐Type Specific Risk Prediction Model
Background: A previously published failure‐type specific risk model showed good performance in the original cohort. Aim: to validate the model and separate patients with high‐ and low‐risk loco‐regional failure (LRF). Goal: to identify patients potentially suitable for treatment intensification trials.Methods: Validation data: 756 patients from two institutions (different countries). Predictive performance was evaluated by Brier scores and AUCs. Discriminatory performance was compared to Union for International Cancer Control (UICC) staging (versions 7 and 8).Results: The model's 3‐year AUC for LRF was 65%, significantly better than UICC7 staging, but no significant difference to UICC8. Model‐based risk stratification and UICC8 both identified high‐risk patient groups with 3‐year LRF ≈30%. The population mean was 18%.Conclusions: The model performed well on a group level. UICC8 staging performed equally well. Although developed for the endpoint of OS, an improvement from UICC version 7 to version 8 was evident also for the prediction of LRF.
- 22 September 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (10) , 1246-1250
Evaluating the dosimetric effect of intra-fractional variations in deep inspiration breath-hold radiotherapy – a proof-of-concept study
- 22 September 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (10) , 1246-1250
Evaluating the dosimetric effect of intra-fractional variations in deep inspiration breath-hold radiotherapy – a proof-of-concept study
- 15 September 2023
- Published by Taylor & Francis in Acta Oncologica
- Vol. 62 (11) , 1369-1374
CBCT-based online adaptive radiotherapy for head and neck cancer – dosimetric evaluation of first clinical experience
- 15 September 2023
- Published by Taylor & Francis in Acta Oncologica
- Vol. 62 (11) , 1369-1374
CBCT-based online adaptive radiotherapy for head and neck cancer – dosimetric evaluation of first clinical experience
- Open Access
- 10 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1360-1368
A systematic review on clinical adaptive radiotherapy for head and neck cancer
"Introducing canine lifestyle medicine and access to care in context of an interprofessional framework" published on 14 May 2023 by American Veterinary Medical Association.
- 10 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (11) , 1360-1368
Open AccessA systematic review on clinical adaptive radiotherapy for head and neck cancer
"Introducing canine lifestyle medicine and access to care in context of an interprofessional framework" published on 14 May 2023 by American Veterinary Medical Association.
- Open Access
- 28 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109771
The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas
- 28 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109771
Open AccessThe influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas
- 21 January 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 59 (5) , 525-533
Radiation dose-painting with protons vs. photons for head-and-neck cancer
Background: Dose-painting has recently been investigated in early-phase trials in head-and-neck cancer (HNC) with the aim of improving local tumor control. At the same time proton therapy has been reported as potentially capable of decreasing toxicity. Here, we investigate whether protons could be applied in a dose-painting setting by comparing proton dose distributions with delivered photon plans from a phase-I trial of FDG-PET based dose-painting at our institution. Material and methods: Eleven oropharynx (5), hypopharynx (2) and larynx cancer (4) patients from the recently conducted phase I trial were used for comparison of proton and photon dose-painting techniques. Robust optimization (3.5%/3 mm) was used for proton plans. Plan robustness and difference in dose metrics to targets and organs at risk were evaluated. Results: The proton plans met target dose constraints, while having lower non-target dose than photon plans (body-minus-CTV, mean dose 3.9 Gy vs 7.2 Gy, p = .004). Despite the use of robust proton planning for plan max dose, photon plan max doses were more robust (p = .006). Max dose to medulla, brainstem and mandible were lower in the proton plans, while there was no significant difference in mean dose to submandibular- and parotid glands. Conclusion: Proton dose-painting for HNC seems feasible and can reduce the non-target dose overall, however not significantly to certain organs close to the target, such as the salivary glands. Max dose in proton plans had a lower robustness compared to photons, requiring caution to avoid unintended hot spots in consideration of the risk of mucosal toxicity.
- 21 January 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 59 (5) , 525-533
Radiation dose-painting with protons vs. photons for head-and-neck cancer
Background: Dose-painting has recently been investigated in early-phase trials in head-and-neck cancer (HNC) with the aim of improving local tumor control. At the same time proton therapy has been reported as potentially capable of decreasing toxicity. Here, we investigate whether protons could be applied in a dose-painting setting by comparing proton dose distributions with delivered photon plans from a phase-I trial of FDG-PET based dose-painting at our institution. Material and methods: Eleven oropharynx (5), hypopharynx (2) and larynx cancer (4) patients from the recently conducted phase I trial were used for comparison of proton and photon dose-painting techniques. Robust optimization (3.5%/3 mm) was used for proton plans. Plan robustness and difference in dose metrics to targets and organs at risk were evaluated. Results: The proton plans met target dose constraints, while having lower non-target dose than photon plans (body-minus-CTV, mean dose 3.9 Gy vs 7.2 Gy, p = .004). Despite the use of robust proton planning for plan max dose, photon plan max doses were more robust (p = .006). Max dose to medulla, brainstem and mandible were lower in the proton plans, while there was no significant difference in mean dose to submandibular- and parotid glands. Conclusion: Proton dose-painting for HNC seems feasible and can reduce the non-target dose overall, however not significantly to certain organs close to the target, such as the salivary glands. Max dose in proton plans had a lower robustness compared to photons, requiring caution to avoid unintended hot spots in consideration of the risk of mucosal toxicity.
- 15 February 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (3) , 390-392
On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer
Loco-regional control (LRC) and disease-free-survival (DFS) are important clinical endpoints in head-and-neck cancer (HNC). However, an improvement in LRC cannot be expected to translate directly i...
- 15 February 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (3) , 390-392
On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer
Loco-regional control (LRC) and disease-free-survival (DFS) are important clinical endpoints in head-and-neck cancer (HNC). However, an improvement in LRC cannot be expected to translate directly i...